Cohance Lifesciences Limited CC-Mar24.pdf
30 May 2024
-
Yes. Thank you for the opportunity. L ike you have given in your presentation pipeline , Phase 3 pipeline for the intermediates for Suven. Similarly, can you share for Cohance as well?
Read in transcript -
Understood. So the kind of traction that we are seeing in the Suve n business, your Phase 3 pipeline is almost doubled, right? If I just look at the number of intermediates from 6 in FY'23 to 13, similar traction have we seen in the Cohance CDMO piece as well?
Read in transcript -
And in terms of reaching out to clients, are we now reaching out to clients as a merged entity or that is still pending? We are still reaching out separately. There's some color around operationally. Is the merger happening or do we wait for the legal merger to happen before we reach out…?
Read in transcript